1 December 2024 - As of 1 December 2024, combination chemotherapy medicines, Opdualag and Vyxeos, will be transitioned from the Highly Specialised Drugs Program to the Efficient Funding of Chemotherapy Program, consistent with recommendations by the PBAC.